Tetracycline

Name: Tetracycline
Brand: MedChemExpress
SKU: HY-A0107
Rating: 5.0 (51 reviews)

Cat. No.: HY-A0107 Purity: 98.0%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Tetracycline is a broad-spectrum antibiotic with oral activity. Tetracycline exhibits activity against a wide range of bacteria including gram-positive, gram-negative bacteria, chlamydiae, mycoplasmas and rickettsiae. Tetracycline can be used for the research of infections.

For research use only. We do not sell to patients.

CAS No. : 60-54-8

Size	Stock	Quantity
200 mg	In-stock	Estimated Time of Arrival: December 31
1 g	In-stock	Estimated Time of Arrival: December 31
5 g	In-stock	Estimated Time of Arrival: December 31
10 g	In-stock	Estimated Time of Arrival: December 31
25 g	In-stock	Estimated Time of Arrival: December 31
50 g	In-stock	Estimated Time of Arrival: December 31
100 g	In-stock	Estimated Time of Arrival: December 31
> 100 g	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 51 publication(s) in Google Scholar

Other Forms of Tetracycline:

51 Publications Citing Use of MCE Tetracycline

Flow Cytometry

Bio/Physico-chemical Assay

Cell Imaging/Staining

Microbiological Assay

: Tetracycline purchased from MedChemExpress. Usage Cited in: iScience. 2025 Nov 17;28(12):114102.; We performed dual RNA-seq on phorbol 12-myristate 13-acetate (PMA)-differentiated THP-1 macrophages sub-populations infected with double-fluorescent-engineered H37Ra in vitro. This strain constitutively expressed Emerald (green) and expressed TagRFP (red) only upon Tetracycline hydrochloride induction, enabling discrimination of bacterial viability by fluorescence-activated cell sorting (FACS).

: Tetracycline purchased from MedChemExpress. Usage Cited in: AMB Express. 2024 Dec 24;14(1):141. [Abstract]; Combinational antimicrobial effects between PVB and conventional antibiotics against MRSA ATCC 43,300. TET, Tetracycline. DOX, Doxycycline. E, Erythromycin. AZI, Azithromycin. P, Penicillin. CAZ, Ceftazidime. AMP, Ampicillin. CEZ, Cefazolin. CEF, Cefotaxime. OXA, Oxacillin. CRO, Ceftriaxone. AMK, Amikacin. GEN, Gentamycin, KANA, Kanamycin. TOB, Tobramycin. SPC, Spectinomycin.

: Tetracycline purchased from MedChemExpress. Usage Cited in: J Extracell Vesicles. 2024 Jul;13(7):e12468. [Abstract]; The protein levels of HEXB in HBV replication cell model. Left, Tetracycline was added to inhibit HBV replication in HepAD38 cells. Right, HepG2.2.15 was treated with NAC (1 mM, 12 h) to abolish ROS produced by HBV replication.

: Tetracycline purchased from MedChemExpress. Usage Cited in: Microorganisms. 2024 Mar 13;12(3):575.; Percentages of E. coli strains showing antimicrobial resistance to different antimicrobial agents. AMP, Ampicillin; CAZ, Ceftazidime; IPM, Imipenem; MRP, Meropenem; GEN, Gentamicin; OFX, Ofloxacin; SXT, Trimethoprim–sulfamethoxazole; TET, Tetracycline; TGC, Tigecycline; CL, Colistin; FFC, Florfenicol.

: Tetracycline purchased from MedChemExpress. Usage Cited in: J Clin Invest. 2023 Apr 17;133(8):e159941. [Abstract]; THP-1–derived macrophages were infected for 72 hours with Mtb strain H37Ra carrying a dual-color reporter that comprises a constitutively green (Emerald) and a Tetracycline-inducible red (TagRFP) fluorescent protein. Tetracycline (500 ng/mL) was added 24 hours before analysis of the live or dead status of the H37Ra strain in macrophages by flow cytometry.

: Tetracycline purchased from MedChemExpress. Usage Cited in: EBioMedicine. 2022 Apr;78:103943. [Abstract]; Microdilution checkerboard analysis showed that plumbagin restored the susceptibility of tet(X4)-carrying E. coli J53p47EC and K. pneumoniae K12016p47EC to Tetracycline, in comparison to the tet(X4)-negative strains E. coli J53 and K. pneumoniae K12016.

: Tetracycline purchased from MedChemExpress. Usage Cited in: EBioMedicine. 2022 Apr;78:103943. [Abstract]; Time-killing assays of resistant E. coli DH5α+pAM401-tet(X4) by a combination of Tetracycline (8 μg/mL, 0-24 h) and Plumbagin.

: Tetracycline purchased from MedChemExpress. Usage Cited in: EBioMedicine. 2022 Apr;78:103943. [Abstract]; Synergistic mechanisms of plumbagin in combination with tetracycline. An accelerated TCA cycle was observed after the treatment with the combination of Plumbagin and Tetracycline (16 and 32 μg/mL).

: Tetracycline purchased from MedChemExpress. Usage Cited in: Cell Res. 2020 Dec;30(12):1063-1077. [Abstract]; Immunoblotting analysis of MLKL-Flag, tBid-Flag, and Cleaved Caspase-3 expression in cell death-inducible C2C12 cell lines with or without tetracycline treatment. C2C12-Mlkl-TetON cells were treated with 1 μg/mL Tetracycline hydrochloride for 12 h to induce necroptosis, and C2C12-tBid-TetON cells were treated with 1 μg/mL Tetracycline hydrochloride for 6 h to induce apoptosis.

: Tetracycline purchased from MedChemExpress. Usage Cited in: Cell Res. 2020 Dec;30(12):1063-1077. [Abstract]; Representative phase-contrast images of MuSCs cultured in different fractions of NCM after purification. The complete NCM was used as the positive control (NCM input); C2C12-Mlkl-TetON medium without Tetracycline hydrochloride treatment was used as the negative control (Tet-control). Cells were cultured for 48 h. Scale bars, 100 μm.

: Tetracycline purchased from MedChemExpress. Usage Cited in: Cell Res. 2020 Dec;30(12):1063-1077. [Abstract]; Immunoblotting analysis of the expression and extracellular release of TNC upon necroptosis induction at different time points as indicated. C2C12-Mlkl-TetON cells were treated with 1 μg/mL Tetracycline hydrochloride for 12 h to induce necroptosis. Both the whole cell lysates and NCM were harvested and then subjected to immunoblotting analysis using antibodies as indicated.

: Tetracycline purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2020 Jul 21;7(17):2001374. [Abstract]; The pEt_20 polymer mitigates resistance to Azithromycin, Gentamicin, Imipenem, and Tetracycline, and reduces their minimum inhibitory concentration (MIC) to sensitive levels or even lower.

: Tetracycline purchased from MedChemExpress. Usage Cited in: MBio. 2019 Aug 27;10(4). pii: e01949-19. [Abstract]; CD157 deficiency impairs macrophage bactericidal capacity. Peritoneal macrophages from WT mice and Cd157 KO mice treated with sCD157 (+sCD157) (5 μg/ml) or not treated with sCD157 were infected with strain H37Ra harboring a dual-color reporter that comprises a constitutively green (Emerald) and a Tetracycline hydrochloride-inducible red (TagRFP) fluorescent protein for 3 days. Tetracycline hydrochloride (500 ng/ml) was added 24 h before flow cytometry. Macrophages were then harvested and fixed with 4% PFA, and the percentage of cells with live M. tuberculosis (MTB) (red) were determined by FACS.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Antibiotic Isoform Specific Products:

View All Isoforms

Aminoglycoside Glycopeptide Lipopeptide Macrolide Oxazolidinone Quinolone Tetracycline β-lactam

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

Tetracycline

Cellular Effect

Cell Line	Type	Value	Description	References
CCRF-CEM	CC₅₀	40.5 μM Compound: tetracycline	Cytotoxicity against CEM cells after 5 days by MTT method Cytotoxicity against CEM cells after 5 days by MTT method	[PMID: 17376679]
CCRF-CEM	EC₅₀	> 40.5 μM Compound: tetracycline	Antiviral activity against HIV1 3B in CEM cells assessed as inhibition of viral-induced cytopathicity Antiviral activity against HIV1 3B in CEM cells assessed as inhibition of viral-induced cytopathicity	[PMID: 17376679]
HaCaT	IC₅₀	8 μM Compound: Tetracycline	Cytotoxicity against human HaCaT cells after 24 hrs by MTT assay Cytotoxicity against human HaCaT cells after 24 hrs by MTT assay	[PMID: 34223166]
HeLa	IC₅₀	51 μM Compound: Tetracycline	Compound was evaluated for the inhibition of cell proliferation of human cervix epithelioid carcinoma, HeLa (ATCC CCL2). Compound was evaluated for the inhibition of cell proliferation of human cervix epithelioid carcinoma, HeLa (ATCC CCL2).	10.1016/0960-894X(96)00418-0
HeLa	IC₅₀	> 400 μg/mL Compound: Tetracycline	Antiproliferative effect against HeLa cells after 48 hrs Antiproliferative effect against HeLa cells after 48 hrs	[PMID: 17088489]
HepG2	IC₅₀	128 μM Compound: Tetracycline	Compound was evaluated for the inhibition of cell proliferation of human hepatocellular carcinoma, HepG2 (ATCC HB8065). Compound was evaluated for the inhibition of cell proliferation of human hepatocellular carcinoma, HepG2 (ATCC HB8065).	10.1016/0960-894X(96)00418-0
MCF7	IC₅₀	41.6 μM Compound: Tetracycline	Dark toxicity against human MCF7 cells assessed as decrease in cell viability by MTT assay Dark toxicity against human MCF7 cells assessed as decrease in cell viability by MTT assay	[PMID: 29673980]
MG-63	IC₅₀	180 μg/mL Compound: Tetracycline	Antiproliferative effect against MG63 cells assessed as BrdU incorporation into DNA after 48 hrs after 48 hrs Antiproliferative effect against MG63 cells assessed as BrdU incorporation into DNA after 48 hrs after 48 hrs	[PMID: 17088489]
Osteoblast	IC₅₀	180 μg/mL Compound: Tetracycline	Antiproliferative effect against primary human osteoblasts assessed as BrdU incorporation into DNA after 48 hrs Antiproliferative effect against primary human osteoblasts assessed as BrdU incorporation into DNA after 48 hrs	[PMID: 17088489]

In Vitro

Tetracycline shows susceptibilfty of V. vulnlflcus strain B3547 with MIC value of 0.5 g/mL^[2].
Tetracycline inhibits the L-amyloid aggregates formation and disassembles the pre-formed fibrils^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Note:
Please do not refer to only one article to determine the experimental conditions. It is recommended to determine the optimal experimental conditions (animal strain, age, dosage, frequency and cycle, detection time and indicators, etc.) through preliminary experiments before the formal experiment.

Tetracycline can be used in animal modeling to create genetically engineered disease models. The pharmacokinetics of Tetracycline after intraperitoneal administration in broiler chickens exhibit unique distribution and elimination characteristics. Tetracycline distributes widely in the body, with rapid elimination, high clearance, and a large volume of distribution. After oral administration, Tetracycline shows high gastrointestinal absorption and moderate elimination rates. Although the absorption rate of Tetracycline is higher than that of most other tetracycline drugs, its overall drug exposure is relatively low^[4].

Induction of tumor regression based on BCR-ABL gene silencing^[4]

Background

The BCR-ABL gene encodes an abnormal tyrosine kinase (BCR-ABL protein), which leads to uncontrolled cell proliferation. Tetracycline can induce tumor regression in mice by inhibiting BCR-ABL expression through the suppression of the binding between tTA (tetracycline transactivator) and the Tet-OP (Tetracycline Operator) sequence^[4].

Specific Modeling Methods

Mice: nu/nu • female and male • 6-8 weeks old
Administration: 200 μg/ml • po • single dose

Note

1. Tetracycline is administered orally dissolved in drinking water containing 5% sucrose.
2. Mouse tumor model construction: To induce visible tumors, Ba/F3 cells transduced with SIN-p210 (a retrovirus carrying and inducing tetracycline-dependent BCR-ABL gene expression) are subcutaneously injected into nude mice.

Modeling Indicators

Phenotypic observation: The tumors established in the mice completely regress.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female ICR mice weight 30 to 40 g with V.vulnificus strain B3547 infection^[2]
Dosage:	3 mg/kg
Administration:	Intraperitoneal injection; 3 mg/kg every 12h until survive
Result:	Inhibited the growth of human CNE-2 xenografts in nude mice.

Clinical Trial

Molecular Weight

444.43

Formula

C₂₂H₂₄N₂O₈

CAS No.

60-54-8

Appearance

Solid

Color

Light yellow to yellow

SMILES

O=C(C(C1=O)=C(O)[C@@H](N(C)C)[C@]2([H])C[C@]3([H])[C@](C)(O)C4=C(C(C3=C(O)[C@@]21O)=O)C(O)=CC=C4)N

Structure Classification

Initial Source

Microorganisms

Shigella dysenteriae

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years

*The compound is unstable in solutions, freshly prepared is recommended.

Solvent & Solubility

In Vitro:

DMSO : 116.67 mg/mL (262.52 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.2501 mL	11.2504 mL	22.5007 mL
5 mM	0.4500 mL	2.2501 mL	4.5001 mL
10 mM	0.2250 mL	1.1250 mL	2.2501 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (4.68 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (4.68 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*The compound is unstable in solutions, freshly prepared is recommended.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 98.0%

Select Batch:

Data Sheet (285 KB) SDS (419 KB)

COA (255 KB) HNMR (270 KB)

Handling Instructions (2659 KB)

References

[1]. Chopra I, et al. Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology ofbacterial resistance. Microbiol Mol Biol Rev. 2001 Jun;65(2):232-60. [Content Brief]

[2]. Bowdre JH, et al. Antibiotic efficacy against Vibrio vulnificus in the mouse: superiority of tetracycline. J Pharmacol Exp Ther. 1983 Jun;225(3):595-8. [Content Brief]

[3]. Forloni G, et al. Anti-amyloidogenic activity of tetracyclines: studies in vitro. FEBS Lett. 2001 Jan 5;487(3):404-7. [Content Brief]

[4]. Dugray A, et al. Rapid generation of a tetracycline-inducible BCR-ABL defective retrovirus using a single autoregulatory retroviral cassette. Leukemia. 2001 Oct;15(10):1658-62. [Content Brief]

[5]. Ziółkowski H, et al. Comparative pharmacokinetics of chlortetracycline, tetracycline, minocycline, and tigecycline in broiler chickens. Poult Sci. 2020 Oct;99(10):4750-4757. [Content Brief]

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.2501 mL	11.2504 mL	22.5007 mL	56.2518 mL
	5 mM	0.4500 mL	2.2501 mL	4.5001 mL	11.2504 mL
	10 mM	0.2250 mL	1.1250 mL	2.2501 mL	5.6252 mL
	15 mM	0.1500 mL	0.7500 mL	1.5000 mL	3.7501 mL
	20 mM	0.1125 mL	0.5625 mL	1.1250 mL	2.8126 mL
	25 mM	0.0900 mL	0.4500 mL	0.9000 mL	2.2501 mL
	30 mM	0.0750 mL	0.3750 mL	0.7500 mL	1.8751 mL
	40 mM	0.0563 mL	0.2813 mL	0.5625 mL	1.4063 mL
	50 mM	0.0450 mL	0.2250 mL	0.4500 mL	1.1250 mL
	60 mM	0.0375 mL	0.1875 mL	0.3750 mL	0.9375 mL
	80 mM	0.0281 mL	0.1406 mL	0.2813 mL	0.7031 mL
	100 mM	0.0225 mL	0.1125 mL	0.2250 mL	0.5625 mL

Tetracycline Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Tetracycline60-54-8AntibioticBacterialoralbroad-spectrumantibioticbacterialInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Tetracycline

Customer Review

Other Forms of Tetracycline:

Tetracycline Related Antibodies

51 Publications Citing Use of MCE Tetracycline

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Antibiotic Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Tetracycline Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Tetracycline Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report